Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 01.06.2026 1 ACS Nano 1 Actas Urol Esp (Engl Ed) 1 Adv Protein Chem Struct Biol 2 Adv Urol 1 Am J Vet Res 1 Anal Chem 2 Anticancer Res 1 Arch Ital Urol Androl 1 Biol Direct 1 Biomaterials 1 Biomedicines 1 BJU Int 1 BMC Biotechnol 2 BMC Cancer 1 BMC Urol 1 Cancer Genet 1 Cancer Sci 2 Cancer Treat Res Commun 2 Cancers (Basel) 1 Cell Death Discov 1 Commun Biol 1 Curr Issues Mol Biol 1 Cytojournal 2 Discov Oncol 1 Eur Urol 2 Eur Urol Focus 4 Eur Urol Oncol 1 Exp Ther Med 1 Front Immunol 4 Front Oncol 1 Future Oncol 1 Gan To Kagaku Ryoho 1 Hum Mutat 1 Int J Clin Oncol 1 Int J STD AIDS 1 Interdiscip Cardiovasc Thorac Surg 2 J Clin Med 1 J Clin Oncol 1 J Exp Clin Cancer Res 2 J Nanobiotechnology 2 J Robot Surg 2 Life (Basel) 1 Mater Today Bio 1 Medicina (Kaunas) 1 Medicine (Baltimore) 1 Nan Fang Yi Ke Da Xue Xue Bao 1 Nat Nanotechnol 1 NPJ Biofilms Microbiomes 1 Oncol Lett 1 Oncol Res Treat 1 Open Med (Wars) 1 Pathol Res Pract 1 Precis Clin Med 2 Sci Rep 1 Tohoku J Exp Med 1 Toxicol In Vitro 4 Urol Oncol 2 Zhonghua Wai Ke Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Nano

1. SUN Z, Liu J, Fang Y, Ma L, et al
   Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy.
   ACS Nano. 2026 May 23. doi: 10.1021/acsnano.6c00407.
   PubMed         Abstract available
   
   

   
   Actas Urol Esp (Engl Ed)

2. KAYAR K, Kayar R, Ozdemir BB, Karabay E, et al
   Urinary pH and oncologic outcomes after bacillus calmette-guerin in non-muscle invasive bladder cancer: a retrospective cohort study.
   Actas Urol Esp (Engl Ed). 2026 May 25:501995. doi: 10.1016/j.acuroe.2026.501995.
   PubMed         Abstract available
   
   

   
   Adv Protein Chem Struct Biol

3. ELAVARASU SM, Asheem I, M N, S UK, et al
   Transcriptomic insights into epigenetic and immunomodulatory roles of nuclear histone genes in bladder cancer: A bioinformatics approach.
   Adv Protein Chem Struct Biol. 2026;152:77-101.
   PubMed         Abstract available
   
   

   
   Adv Urol

4. SAYGIN H, Bolat S, Kablan D, Yavuz H, et al
   Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.
   Adv Urol. 2026;2026:6524384.
   PubMed         Abstract available
   
   
5. 
   Correction to "Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence".
   Adv Urol. 2026;2026:9810919.
   PubMed         Abstract available
   
   

   
   Am J Vet Res

6. CHOI SH, Kim JK, Kim SH, Ryu MO, et al
   Recurrent pyuria is associated with shorter progression-free survival in dogs with bladder urothelial carcinoma.
   Am J Vet Res. 2026;87:ajvr.
   PubMed         Abstract available
   
   

   
   Anal Chem

7. WANG S, Tang Y, Xu Y, Wang Y, et al
   Discovery of NMP22-Targeting Aptamers for Point-of-Need Test of Bladder Cancer.
   Anal Chem. 2026 May 22. doi: 10.1021/acs.analchem.6c00738.
   PubMed         Abstract available
   
   

   
   Anticancer Res

8. SABBADINI P, Paganoni E, Galeasso L, Depetris I, et al
   Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review.
   Anticancer Res. 2026;46:3517-3522.
   PubMed         Abstract available
   
   
9. KLATTE T, Hofbauer SL, Ebert J, Ecke TH, et al
   Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.
   Anticancer Res. 2026;46:3333-3342.
   PubMed         Abstract available
   
   

   
   Arch Ital Urol Androl

10. NASUTION RFG, Warli SM, Prapiska FF
    Prognostic significance of pretreatment hydronephrosis in radiotherapy-based bladder-preserving strategies for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Arch Ital Urol Androl. 2026 May 29:14945. doi: 10.4081/aiua.2026.14945.
    PubMed         Abstract available
    
    

    
    Biol Direct

11. CHANG Y, Sun N, Liu Y, Jin Z, et al
    Lnc00892 enhances cisplatin sensitivity by inducing apoptosis through the BTAF1/MDM2/STAT5B/XIAP axis in bladder cancer cells.
    Biol Direct. 2026 May 27. doi: 10.1186/s13062-026-00842.
    PubMed         Abstract available
    
    

    
    Biomaterials

12. CHEN J, Ding Z, Lai S, Gan Z, et al
    Nanoparticles-mediated dual metabolic-immunological intervention reverses immunosuppression in muscle invasive bladder cancer.
    Biomaterials. 2026;335:124335.
    PubMed         Abstract available
    
    

    
    Biomedicines

13. UN S, Aydin VK, Kurt O, Lengerova G, et al
    Time-Dependent Effects of Cisplatin on Autophagy Gene Expression in Bladder Cancer Cells.
    Biomedicines. 2026;14:1006.
    PubMed         Abstract available
    
    

    
    BJU Int

14. ABOU CHAKRA M, Alsamarah I, Hougen HY, Zakharia Y, et al
    Computed tomography-derived extracellular volume fraction is associated with high-grade recurrence in non-muscle-invasive bladder cancer treated with intravesical gemcitabine and docetaxel.
    BJU Int. 2026 May 28. doi: 10.1111/bju.70319.
    PubMed         Abstract available
    
    

    
    BMC Biotechnol

15. WEN J, Wei L, Huang J, Zhou L, et al
    Yeast surface display-based screening and preliminary characterization of nectin-4-targeting nanobodies for bladder cancer.
    BMC Biotechnol. 2026 May 23. doi: 10.1186/s12896-026-01170.
    PubMed         Abstract available
    
    

    
    BMC Cancer

16. CHEN C, Liu X, Xu A, Jiang N, et al
    Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
    PubMed         Abstract available
    
    
17. WU Q, Lu P, Zhang X, Qing X, et al
    Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
    BMC Cancer. 2026;26:680.
    PubMed         Abstract available
    
    

    
    BMC Urol

18. MOFID B, Jafari A, Simforoosh N, Basiri A, et al
    Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.
    BMC Urol. 2026 May 25. doi: 10.1186/s12894-026-02187.
    PubMed         Abstract available
    
    

    
    Cancer Genet

19. MORRIS G, Vlachostergios PJ, Rai MP, Scherr D, et al
    19q13 amplification with AKT2 and ERCC2 gains in sarcomatoid carcinoma of the urinary bladder.
    Cancer Genet. 2026;304-305:51-57.
    PubMed         Abstract available
    
    

    
    Cancer Sci

20. HONG X, Hong T, Liu X, Yao P, et al
    UBE2C-Mediated CD147-CTLA-4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer.
    Cancer Sci. 2026 May 27. doi: 10.1111/cas.70430.
    PubMed         Abstract available
    
    

    
    Cancer Treat Res Commun

21. MIYAKE M, Minegishi T, Aikawa T, Fukasawa T, et al
    Real-world perioperative systemic treatment patterns and outcomes in patients with urothelial carcinoma undergoing radical surgery.
    Cancer Treat Res Commun. 2026;47:101241.
    PubMed         Abstract available
    
    
22. JAN HC, Su YC, Huang SK, Wang CA, et al
    HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma.
    Cancer Treat Res Commun. 2026;47:101148.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

23. MOHAMED NE, Berry DL, McReynolds J, Korn T, et al
    Development and Evaluation of the Personal Patient Profile-Bladder Cancer (P3-BC): A Web-Based Decision Support System for Patients Considering Cystectomy and Urinary Diversion.
    Cancers (Basel). 2026;18:1501.
    PubMed         Abstract available
    
    
24. NEWMAN A, Hansel S, Gerrard G, Orton L, et al
    Real-World Evaluation of Uromonitor((R)) for Bladder Cancer Detection and Surveillance.
    Cancers (Basel). 2026;18:1650.
    PubMed         Abstract available
    
    

    
    Cell Death Discov

25. WEI W, Xiao X, Ren C, Zhang H, et al
    Inhibition of TGM2 enhances cisplatin sensitivity in MSH2-deficient bladder cancer.
    Cell Death Discov. 2026 May 28. doi: 10.1038/s41420-026-03182.
    PubMed         Abstract available
    
    

    
    Commun Biol

26. DUCCI G, Ciufolini G, Campioni G, Pasquale V, et al
    FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.
    Commun Biol. 2026 May 23. doi: 10.1038/s42003-026-10356.
    PubMed         Abstract available
    
    

    
    Curr Issues Mol Biol

27. LI W, Liu D, Yin Q, Geng Y, et al
    Natural Products Targeting Acetylation in Bladder Cancer: Mechanistic Basis, Therapeutic Potential, and Future Perspectives.
    Curr Issues Mol Biol. 2026;48:489.
    PubMed         Abstract available
    
    

    
    Cytojournal

28. HU K, Luo L, Li P, Wang X, et al
    Fibrinogen-like protein 1 induces the formation of an immunosuppressive microenvironment by upregulating fibronectin 1 to promote immune evasion in bladder cancer.
    Cytojournal. 2026;23:25.
    PubMed         Abstract available
    
    

    
    Discov Oncol

29. OZALP FR, Ellez HI, Arslan AM, Demirciler E, et al
    Integrative in silico transcriptomic and pharmacogenomic analysis of CD276 as a candidate prognostic biomarker and therapeutic target in bladder cancer.
    Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05310.
    PubMed         Abstract available
    
    
30. AIZEZI X, Silafu B, Shi H, Huang J, et al
    Multi-omics analysis reveals TM4SF19 as a diagnostic and prognostic biomarker in bladder cancer.
    Discov Oncol. 2026 May 25. doi: 10.1007/s12672-026-05304.
    PubMed         Abstract available
    
    

    
    Eur Urol

31. MAIORANO BA, Dizman N, Necchi A
    Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma.
    Eur Urol. 2026;89:479-482.
    PubMed         Abstract available
    
    

    
    Eur Urol Focus

32. LIU T, Zhu C, Yan Z
    Re: Hayne D, Zhang AY, Thomas H, et al. Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette-Guerin-naive Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In press. h
    Eur Urol Focus. 2026 May 27:S2405-4569(26)00087.
    PubMed        
    
    
33. HAYNE D, Zhang AY, Thomas H, Redfern AD, et al
    Reply to Tonghu Liu's Letter to the Editor re: Bacillus Calmette-Guerin Plus Mitomycin Versus Bacillus Calmette-Guerin Alone for Bacillus Calmette Guerin-naive Non-Muscle-Invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). Eur Urol. In p
    Eur Urol Focus. 2026 May 27:S2405-4569(26)00088.
    PubMed        
    
    

    
    Eur Urol Oncol

34. ZHAO H, Liao J, Wing Sze HV, Liu K, et al
    EZH2 Inhibition Remodels Cell States and Enhances EGFRi Sensitization in Bladder Cancer.
    Eur Urol Oncol. 2026 May 28:S2588-9311(26)00137.
    PubMed         Abstract available
    
    
35. GONTERO P, Perry R, Bridge D, Delattre DD, et al
    Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non-muscle-invasive Bladder Cancer: An Expert Consensus.
    Eur Urol Oncol. 2026 May 29:S2588-9311(26)00134.
    PubMed         Abstract available
    
    
36. NECCHI A, Brembilla G, Whiting K, Arita Y, et al
    AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy.
    Eur Urol Oncol. 2026 May 29:S2588-9311(26)00133.
    PubMed         Abstract available
    
    
37. RAMMANT E, Fox L, De Padova S, Liedberg F, et al
    Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.
    Eur Urol Oncol. 2026 May 26:S2588-9311(26)00125.
    PubMed         Abstract available
    
    

    
    Exp Ther Med

38. HUANG Z, Wang T, Xia W, Li Q, et al
    [Retracted]Oblongifolin C reverses GEM resistance via suppressing autophagy flux in bladder cancer cells.
    Exp Ther Med. 2026;32:186.
    PubMed         Abstract available
    
    

    
    Front Immunol

39. ZHU C, Lu J, Zhu B, Liu B, et al
    ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer.
    Front Immunol. 2026;17:1743064.
    PubMed         Abstract available
    
    

    
    Front Oncol

40. CHEN L, Hang G, Wen Q, Ren L, et al
    Application and challenges of smart responsive multifunctional nanoplatforms in integrated diagnosis and treatment of bladder cancer and overcoming therapeutic resistance.
    Front Oncol. 2026;16:1803259.
    PubMed         Abstract available
    
    
41. WANG M, Chen J, Wang C, He Y, et al
    Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review.
    Front Oncol. 2026;16:1745178.
    PubMed         Abstract available
    
    
42. LI C, Fang R, Wang J, Wang Y, et al
    Urinary DNA methylation biomarkers for bladder cancer diagnosis: a single center case-control study.
    Front Oncol. 2026;16:1812094.
    PubMed         Abstract available
    
    
43. RAHMAN SN, Keervani K, Zhao X, Perry CJ, et al
    Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.
    Front Oncol. 2026;16:1807817.
    PubMed         Abstract available
    
    

    
    Future Oncol

44. SHORE ND, Powles TB, Bedke J, Galsky MD, et al
    Sasanlimab taken together with Bacillus Calmette-Guerin (BCG) compared with BCG alone in people with high-risk non-muscle invasive bladder cancer: a plain language summary.
    Future Oncol. 2026 May 24:1-13. doi: 10.1080/14796694.2026.2671256.
    PubMed        
    
    

    
    Gan To Kagaku Ryoho

45. HAYASHI J, Sugimoto K, Kochi S, Toake M, et al
    [A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].
    Gan To Kagaku Ryoho. 2026;53:307-309.
    PubMed         Abstract available
    
    

    
    Hum Mutat

46. TANG C, Liu Y, Wang TL, Ma J, et al
    Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.
    Hum Mutat. 2026;2026:2797474.
    PubMed         Abstract available
    
    

    
    Int J Clin Oncol

47. NIWA K, Iinuma K, Nakano M, Tomioka M, et al
    Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.
    Int J Clin Oncol. 2026;31:1008-1016.
    PubMed         Abstract available
    
    

    
    Int J STD AIDS

48. ZHANG M, Liu H, Zhang Y, Zhu Z, et al
    HIV-related bladder cancer: A ten-year experience.
    Int J STD AIDS. 2026 May 22:9564624261449133. doi: 10.1177/09564624261449133.
    PubMed         Abstract available
    
    

    
    Interdiscip Cardiovasc Thorac Surg

49. BONNI S, Ramnath NWM, Selten K, Moza A, et al
    Bacillus Calmette-Guerin-Related Mycotic Pseudoaneurysm in the Aortic Arch: Clinical and Operative Challenges.
    Interdiscip Cardiovasc Thorac Surg. 2026;41:ivag120.
    PubMed         Abstract available
    
    

    
    J Clin Med

50. KIM SH, Gudlavalleti H, Lerner SP
    Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
    J Clin Med. 2026;15:3830.
    PubMed         Abstract available
    
    
51. KIM KH, Kang BJ, Lee CH, Kim S, et al
    Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette-Guerin Versus Gemcitabine in Treatment-Naive Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective Analysis.
    J Clin Med. 2026;15:3890.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

52. CATHOMAS R, Petrausch U, Hayoz S, Spahn M, et al
    Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19.
    J Clin Oncol. 2026 May 29:101200JCO2600845. doi: 10.1200/JCO-26-00845.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

53. ZHENG L, Wang J, Han S, Zhong L, et al
    Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
    J Exp Clin Cancer Res. 2026;45:128.
    PubMed        
    
    

    
    J Nanobiotechnology

54. LI Y, Ye F, Liu G, Cheng L, et al
    Nano-armed bcg delivers Cu-Fe MOF to trigger dual cell death in bladder cancer.
    J Nanobiotechnology. 2026 May 29. doi: 10.1186/s12951-026-04590.
    PubMed         Abstract available
    
    
55. QIN X, Zheng B, Liu D, Quan X, et al
    A 'two-in-one' tumor-specific-hydrogel-assisted strategy for intravesical chemotherapy and protection of normal tissues.
    J Nanobiotechnology. 2026;24:502.
    PubMed         Abstract available
    
    

    
    J Robot Surg

56. ZHAO L, Chen HM, Li YT, Zhang T, et al
    Comparative efficacy and safety of open, laparoscopic, and robot-assisted radical cystectomy: a systematic review and network meta-analysis.
    J Robot Surg. 2026;20:552.
    PubMed         Abstract available
    
    
57. CHEN IA, Luo HL, Chu CH, Yu CC, et al
    Robotic versus laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma: comparable oncologic outcomes with reduced intravesical recurrence in pathological T3 disease.
    J Robot Surg. 2026;20:549.
    PubMed         Abstract available
    
    

    
    Life (Basel)

58. GODLEWSKI D, Aebisher D, Bartusik-Aebisher D, Dynarowicz K, et al
    Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.
    Life (Basel). 2026;16:828.
    PubMed         Abstract available
    
    
59. SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
    Systems Biology and Multi-Omics Determinants of Response to Bladder-Preserving Trimodality Therapy in Muscle-Invasive Bladder Cancer.
    Life (Basel). 2026;16:826.
    PubMed         Abstract available
    
    

    
    Mater Today Bio

60. XU Y, Zhao C, Fu S, Wu Y, et al
    Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.
    Mater Today Bio. 2026;38:103222.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

61. KARAKAYALI A, Seyyar M, Sanci PC, Sahin E, et al
    Prognostic Value of the Prognostic Nutritional Index in Patients with Locally Advanced Bladder Cancer Receiving Perioperative Chemotherapy: A Multicenter Real-World Study.
    Medicina (Kaunas). 2026;62:992.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

62. WANG M, Jia K, Wang Y, Yuan D, et al
    The impact of the COVID-19 pandemic in 2020 on the diagnosis, treatment, and cancer-specific survival of major urological cancers: An observational study.
    Medicine (Baltimore). 2026;105:e48966.
    PubMed         Abstract available
    
    

    
    Nan Fang Yi Ke Da Xue Xue Bao

63. SUN R, Li Y, Zuo L, Tao J, et al
    [Myricetin inhibits proliferation and migration of bladder cancer cells by inhibiting HSP90AA1-mediated AKT phosphorylation].
    Nan Fang Yi Ke Da Xue Xue Bao. 2026;46:1039-1052.
    PubMed         Abstract available
    
    

    
    Nat Nanotechnol

64. YIM W, Kang H, Kang BH, McGinnis ME, et al
    Chemical efflux imaging using an annular nanosensor array for in situ bladder cancer detection.
    Nat Nanotechnol. 2026 May 27. doi: 10.1038/s41565-026-02172.
    PubMed         Abstract available
    
    

    
    NPJ Biofilms Microbiomes

65. CAMPO-PEREZ V, Guallar-Garrido S, Cabrera-Rubio R, Herrero-Abadia P, et al
    Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.
    NPJ Biofilms Microbiomes. 2026 May 25. doi: 10.1038/s41522-026-01002.
    PubMed         Abstract available
    
    

    
    Oncol Lett

66. COSKUN A, Sahin AB, Kabul S, Dagtekin ME, et al
    Prognostic significance of squamous differentiation in pT2N0 urothelial bladder cancer.
    Oncol Lett. 2026;32:299.
    PubMed         Abstract available
    
    

    
    Oncol Res Treat

67. ZHANG XW, Schlack K, Hartmann A, Steiner T, et al
    Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-invasive Bladder Cancer.
    Oncol Res Treat. 2026 May 29:1-8. doi: 10.1159/000552743.
    PubMed         Abstract available
    
    

    
    Open Med (Wars)

68. ZHAO X, Xu X
    ARAF regulates malignant progression of bladder cancer through the p38MAPK pathway.
    Open Med (Wars). 2026;21:20261422.
    PubMed         Abstract available
    
    

    
    Pathol Res Pract

69. MUSANGILE FY, Matsuzaki I, Nishikawa T, Kojima F, et al
    Precursor flat urothelial lesions: Molecular landscape, pathogenesis, and biological insights.
    Pathol Res Pract. 2026;284:156517.
    PubMed         Abstract available
    
    

    
    Precis Clin Med

70. LI Z, Zhong H, Baptista-Hon D, Qiu J, et al
    JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study.
    Precis Clin Med. 2026;9:pbag012.
    PubMed         Abstract available
    
    

    
    Sci Rep

71. ZHENG H, Tian Y, Cai Z, Huang G, et al
    CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation.
    Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-48969.
    PubMed         Abstract available
    
    
72. JUNG M, Park S, Jang I, Han D, et al
    Ethnicity-specific molecular subtypes and a machine-learning risk model in Asian patients with non-muscle-invasive bladder cancer.
    Sci Rep. 2026 May 29. doi: 10.1038/s41598-026-55438.
    PubMed         Abstract available
    
    

    
    Tohoku J Exp Med

73. MA M, Wu H, Zhu D, Sun P, et al
    The Mechanistic Role of the lncRNA AC016876.2/miR-133a-3p/SPAG5 Axis in Regulating Autophagy and Malignant Behavior in Bladder Cancer Cells.
    Tohoku J Exp Med. 2026 May 28. doi: 10.1620/tjem.2026.
    PubMed        
    
    

    
    Toxicol In Vitro

74. KOBYLKA P, Murias M, Bakun P, Goslinski T, et al
    Cellular responses to morpholinated curcumin derivatives in human muscle-invasive bladder cancer cells.
    Toxicol In Vitro. 2026;115:106251.
    PubMed         Abstract available
    
    

    
    Urol Oncol

75. MAMTANI R, Squires P, Mojebi A, Hale B, et al
    Neoadjuvant, adjuvant, and perioperative therapy comparisons in muscle-invasive bladder cancer: Clinical and methodological considerations for the interpretation of network meta-analytic findings.
    Urol Oncol. 2026 May 27:S1078-1439(26)00495.
    PubMed        
    
    
76. PRADHAN B, Mishra P, Dash P, Niharika, et al
    Epigenetic signatures and risk determinants in bladder cancer: Implications for diagnostic and therapeutic interventions.
    Urol Oncol. 2026 May 22:S1078-1439(26)00498.
    PubMed         Abstract available
    
    
77. CARLSEN B, Klingen TA, Andreassen BK, Beisland C, et al
    Tumor cell invasion in blood vessels but not lymphatic vessels in TURBT predicts poor prognosis in bladder cancer.
    Urol Oncol. 2026;44:26-35.
    PubMed         Abstract available
    
    
78. PALERU G, Singathala GS, Kural S, Kumar L, et al
    Emerging role of urinary biomarkers in bladder cancer diagnosis and prognosis.
    Urol Oncol. 2026;44:70-81.
    PubMed         Abstract available
    
    

    
    Zhonghua Wai Ke Za Zhi

79. ZHONG WL, Zheng HR, Lin TX
    [Liquid biopsy empowers precision medicine across the full course of bladder cancer].
    Zhonghua Wai Ke Za Zhi. 2026;64:695-700.
    PubMed         Abstract available
    
    
80. ZHANG N, Liang H, Wang L, Yang T, et al
    [Investigating prognostic factors for T1 stage high-grade bladder cancer and developing a multi-marker risk prediction model using immunohistochemistry].
    Zhonghua Wai Ke Za Zhi. 2026;64:768-777.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum